Health Economics Review

Papers
(The H4-Index of Health Economics Review is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
COVID-19 and the efficiency of health systems in Europe75
Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review66
Micro-costing in health and medicine: a critical appraisal39
Health system efficiency in OECD countries: dynamic network DEA approach37
Hospitalization budget impact during the COVID-19 pandemic in Spain25
COVID-19 healthcare cost and length of hospital stay in Turkey: retrospective analysis from the first peak of the pandemic25
A systematic review and meta-analysis of unmet needs for healthcare and long-term care among older people23
The fragile healthcare system in Lebanon: sounding the alarm about its possible collapse22
How innovation can be defined, evaluated and rewarded in health technology assessment22
The costs associated with stroke care continuum: a systematic review21
Which factors increase informal care hours and societal costs among caregivers of people with dementia? A systematic review of Resource Utilization in Dementia (RUD)20
Systematic review and validity assessment of methods used in discrete choice experiments of primary healthcare professionals16
How can a joint European health technology assessment provide an ‘additional benefit’ over the current standard of national assessments?16
Epidemics, pandemics and income inequality15
Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry14
Does less working time improve life satisfaction? Evidence from European Social Survey14
Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective14
Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis14
0.040776968002319